Your browser is no longer supported. Please, upgrade your browser.
Settings
SIOX [NASD]
Sio Gene Therapies Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own27.10% Shs Outstand72.86M Perf Week14.22%
Market Cap175.79M Forward P/E- EPS next Y-0.85 Insider Trans0.00% Shs Float54.08M Perf Month19.31%
Income-35.70M PEG- EPS next Q-0.17 Inst Own30.40% Short Float2.75% Perf Quarter-15.14%
Sales- P/S- EPS this Y78.80% Inst Trans5.26% Short Ratio2.46 Perf Half Y-3.98%
Book/sh1.55 P/B1.55 EPS next Y-21.40% ROA-32.80% Target Price- Perf Year-48.94%
Cash/sh- P/C- EPS next 5Y- ROE-36.10% 52W Range1.76 - 5.74 Perf YTD-13.31%
Dividend- P/FCF- EPS past 5Y44.00% ROI- 52W High-59.84% Beta1.69
Dividend %- Quick Ratio15.70 Sales past 5Y- Gross Margin- 52W Low30.97% ATR0.13
Employees42 Current Ratio15.70 Sales Q/Q- Oper. Margin- RSI (14)56.73 Volatility7.15% 6.53%
OptionableYes Debt/Eq0.00 EPS Q/Q17.90% Profit Margin- Rel Volume0.75 Prev Close2.41
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume603.90K Price2.31
Recom1.40 SMA204.84% SMA509.22% SMA200-8.48% Volume245,189 Change-4.36%
Jul-12-21Resumed Chardan Capital Markets Buy $12.50
Jun-15-21Initiated BTIG Research Buy $8
Jun-09-21Reiterated H.C. Wainwright Buy $8
Apr-30-21Reiterated H.C. Wainwright Buy $8
Apr-30-21Initiated H.C. Wainwright Buy $8
Sep-23-21 07:30AM  
Sep-13-21 12:16PM  
Sep-09-21 07:00AM  
Aug-12-21 07:00AM  
Jul-13-21 06:46AM  
Jun-09-21 07:00AM  
May-19-21 08:00AM  
May-14-21 05:46AM  
May-13-21 07:00AM  
Apr-28-21 07:00AM  
Mar-29-21 08:00AM  
Mar-15-21 08:34AM  
07:00AM  
Mar-11-21 08:00AM  
Feb-16-21 07:00AM  
Feb-09-21 07:00AM  
Feb-04-21 07:00AM  
Feb-03-21 07:00AM  
Jan-12-21 04:59AM  
Jan-04-21 08:00AM  
Dec-15-20 04:01PM  
Dec-02-20 07:00AM  
Nov-19-20 08:00AM  
Nov-18-20 10:15PM  
Nov-14-20 06:30PM  
Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cheruvu PavanChief Executive OfficerMar 23Buy2.48100,000248,180180,426Mar 24 07:21 PM
Pande AtulDirectorNov 24Buy2.3410,00023,39933,370Nov 25 09:07 PM